Oppenheimer analysts reaffirmed Zimmer Biomet's "outperform" rating, according to Wallstreet.org.
Here are four notes:
1. On Feb. 8, Oppenheimer cut Zimmer Biomet's price target to $120.
2. Following the price target reduction, the shares hit $90.75 per share, down nearly 4.5 percent.
3. Since July 2015, Zimmer Biomet's shares have decreased 12.18 percent.
4. The shares have underperformed the S&P 500 by 2.71 percent.
More articles on devices:
FDA schedules meeting to review Cartiva's PMA for synthetic cartilage implant: 4 points
Zimmer Biomet investors to offer 11M+ shares of common stock: 5 takeaways
Stryker director sells 12k shares, soon after Sage Products acquisition & potential Moody's downgrade: 7 points